JAMA Neurol:早发性多发性硬化患者认知下降速度增加

2019-06-24 MedSci MedSci原创

研究发现,青少年多发性硬化患者成年后的认知下降速率高于成年患者,需进一步了解早发性多发性硬化症对认知结果影响的机制

多发性硬化(MS)认知障碍可能导致生活质量和社会功能下降。近日研究人员就对青少年多发性硬化(POMS)患者的长期认知进行了调查。

研究人员考察了截止2018年4月,瑞典64个神经科诊所,总计包含8247名18-55岁患者信息,通过考察符号数字模式测验(SDMT)分数评估患者认知状态,比较18岁以前发病人群(POMS)与18岁以后发病人群(AOMS)的认知能力差异。

在5704人中,女性4015人(70.4%),有复发病史者5569人(97.6%)。大多数参与者在随访期间接受了疾病修饰疗法(DMT,98.8%)。POMS组基线年龄中位数为25.6岁,AOMS组为38.3岁。共分析了46429个SDMT评分。经性别、年龄、病程、SDMTs总数、SDMT形式、DMT剂量的调整后,POMS患者的β评分显著低于AOMS患者(β系数-3.59)。POMS患者的SDMT评分下降快于AOMS患者(β系数-0.30)。POMS组的认知障碍发生率也显著升高(OR:1.44)。

研究发现,青少年多发性硬化患者成年后的认知下降速率高于成年患者,需进一步了解早发性多发性硬化症对认知结果影响的机制。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1664074, encodeId=078116640e459, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon Aug 05 20:20:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000800, encodeId=51b22000800af, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Dec 12 10:20:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890024, encodeId=31041890024ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 27 14:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028587, encodeId=4890202858e1d, content=<a href='/topic/show?id=bc58912088f' target=_blank style='color:#2F92EE;'>#认知下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91208, encryptionId=bc58912088f, topicName=认知下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 27 19:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369984, encodeId=67793699846c, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57e02460470, createdName=12417aa2m07暂无昵称, createdTime=Sat Jul 20 10:23:12 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368314, encodeId=ced3368314d5, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Tue Jun 25 07:47:19 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1664074, encodeId=078116640e459, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon Aug 05 20:20:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000800, encodeId=51b22000800af, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Dec 12 10:20:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890024, encodeId=31041890024ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 27 14:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028587, encodeId=4890202858e1d, content=<a href='/topic/show?id=bc58912088f' target=_blank style='color:#2F92EE;'>#认知下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91208, encryptionId=bc58912088f, topicName=认知下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 27 19:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369984, encodeId=67793699846c, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57e02460470, createdName=12417aa2m07暂无昵称, createdTime=Sat Jul 20 10:23:12 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368314, encodeId=ced3368314d5, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Tue Jun 25 07:47:19 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
    2019-12-12 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1664074, encodeId=078116640e459, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon Aug 05 20:20:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000800, encodeId=51b22000800af, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Dec 12 10:20:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890024, encodeId=31041890024ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 27 14:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028587, encodeId=4890202858e1d, content=<a href='/topic/show?id=bc58912088f' target=_blank style='color:#2F92EE;'>#认知下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91208, encryptionId=bc58912088f, topicName=认知下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 27 19:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369984, encodeId=67793699846c, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57e02460470, createdName=12417aa2m07暂无昵称, createdTime=Sat Jul 20 10:23:12 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368314, encodeId=ced3368314d5, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Tue Jun 25 07:47:19 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
    2019-11-27 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=1664074, encodeId=078116640e459, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon Aug 05 20:20:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000800, encodeId=51b22000800af, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Dec 12 10:20:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890024, encodeId=31041890024ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 27 14:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028587, encodeId=4890202858e1d, content=<a href='/topic/show?id=bc58912088f' target=_blank style='color:#2F92EE;'>#认知下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91208, encryptionId=bc58912088f, topicName=认知下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 27 19:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369984, encodeId=67793699846c, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57e02460470, createdName=12417aa2m07暂无昵称, createdTime=Sat Jul 20 10:23:12 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368314, encodeId=ced3368314d5, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Tue Jun 25 07:47:19 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1664074, encodeId=078116640e459, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon Aug 05 20:20:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000800, encodeId=51b22000800af, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Dec 12 10:20:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890024, encodeId=31041890024ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 27 14:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028587, encodeId=4890202858e1d, content=<a href='/topic/show?id=bc58912088f' target=_blank style='color:#2F92EE;'>#认知下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91208, encryptionId=bc58912088f, topicName=认知下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 27 19:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369984, encodeId=67793699846c, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57e02460470, createdName=12417aa2m07暂无昵称, createdTime=Sat Jul 20 10:23:12 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368314, encodeId=ced3368314d5, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Tue Jun 25 07:47:19 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
    2019-07-20 12417aa2m07暂无昵称

    666

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1664074, encodeId=078116640e459, content=<a href='/topic/show?id=a20c59283e5' target=_blank style='color:#2F92EE;'>#早发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59283, encryptionId=a20c59283e5, topicName=早发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06c425715601, createdName=ms7258648636991762, createdTime=Mon Aug 05 20:20:00 CST 2019, time=2019-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000800, encodeId=51b22000800af, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Dec 12 10:20:00 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890024, encodeId=31041890024ee, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43089, encryptionId=760c430895a, topicName=多发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Wed Nov 27 14:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2028587, encodeId=4890202858e1d, content=<a href='/topic/show?id=bc58912088f' target=_blank style='color:#2F92EE;'>#认知下降#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91208, encryptionId=bc58912088f, topicName=认知下降)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Nov 27 19:20:00 CST 2019, time=2019-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369984, encodeId=67793699846c, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=57e02460470, createdName=12417aa2m07暂无昵称, createdTime=Sat Jul 20 10:23:12 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368314, encodeId=ced3368314d5, content=666, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/01/04/2540fb84decb81d47a7f2868070e6cbd.jpg, createdBy=ed3f2205793, createdName=百草, createdTime=Tue Jun 25 07:47:19 CST 2019, time=2019-06-25, status=1, ipAttribution=)]
    2019-06-25 百草

    666

    0

相关资讯

我国首部《多发性硬化患者生存报告(2018)》发布

在2月28日国际罕见病日到来之际,中华医学会神经病学分会、中国医疗保健国际交流促进会2月24日在北京共同发布中国首部《多发性硬化患者生存报告(2018)》。这是我国首个覆盖全国范围、以患者角度出发的多发性硬化患者调研,涵盖患者基本特征、疾病特征、诊疗情况、心理负担及经济负担五大方面,多维度揭示了中国多发性硬化患者生存现状。报告呼吁提高中国多发性硬化疾病认知、诊疗水平、社会保障等,以帮助患者提升生活

Neurology:矿物质摄入量与多发性硬化风险

由此可见,该研究结果表明矿物质摄入不是MS风险的重要决定因素。

Radiology:定量MRI颅脑铁沉积与多发性硬化的相关性

本研究旨在利用定量磁敏感图(QSM)研究多发性硬化(MS)患者深部灰质磁敏感性并评价磁敏感性与临床残疾的相关性。

NATURE:人类多发性硬化症中少突胶质细胞异质性改变

至今为止,人类OL异质性的程度及其对MS病理学的可能贡献仍然未知。

J Neurol Neurosur Ps:自然绝经对多发性硬化的影响

由此可见,自然绝经似乎是MS进展阶段的转折点。更年期后复发率也会降低,但这种影响可能主要是由于衰老和慢性疾病患者转为进展期。吸烟可以加速绝经后的残疾进展。

NEJM:口服BTK抑制剂治疗多发性硬化

研究认为,复发性多发性硬化症患者每日服用一次75毫克Evobrutinib,可显著减少钆增强病变明数目,但不同疗法年化复发率或残疾进展均无显著性差异